Venture capital-backed gene therapy specialist uniQure plans to raise $75m via an IPO on the Nasdaq exchange, according to a filing with US securities regulators.
The company, which is backed by Advent Venture Partners, Coller Capital and Forbion Capital Partners, did not say how many shares it was looking to float and at what price.
Jefferies, Leerink Swann and Piper Jaffray are acting as lead underwriters for the IPO and uniQure will trade under the symbol QURE, the filing showed.
UniQure’s first product, Glybera, was approved by the European Commission in October 2012 for the treatment of patients with lipoprotein lipase deficiency.
Glybera is expected to be commercially launched in some European countries in the first half of this year via the company’s partnership with Chiesi Farmaceutici, which was signed in April last year.
In August and December last year the company held meetings with the US Food and Drug Administration and it plans to file an investigational new drug application in the US this year.
In November one of uniQure’s investors, Advent, made a €1.17bn cash offer for Dutch business software company UNIT4.
Copyright © 2014 AltAssets